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The immune system has a long-recognized ability 
to target select proteins produced by tumor cells. Such 
tumor-specific antigens may be uniquely present in 
cancer as a result of mutations or abnormal protein 
modifications. In other cases, the increased 
immunogenicity of structurally normal proteins is less 
obvious and may represent, albeit not always, elevated 
levels of their expression in malignant cells. Immune 
response to tumor-specific antigens raises two 
important questions: could it be selectively enhanced 
for a therapeutic effect, and could it be used to discover 
the actual antigens in order to understand the properties 
of the tumors and to diagnose and classify the disease? 
The thought-provoking report by Ionov in the current 
issue of this journal offers news insights into advancing 
both of these issues [1].  
The experimental approach (See Figure) relies on 
the use of a phage-display library, which is first 
depleted of the phages that bind to control antibodies, 
such as the ones obtained from a healthy donor, and 
then  is subjected to precipitation using an antibody 
fraction from a cancer patient. The phages enriched at 
this step are expected to display the peptides that are 
recognized by patient’s, but not control’s antibodies. 
The unbound phages are eliminated, while the 
precipitated ones could be rescued in bacteria. This 
sequence of steps could be repeated multiple times for 
further enrichment. Subsequently, the sequence of the 
presented peptides is determined by sequencing the 
enriched phages. These  data are examined for 
homology to known human proteins. Not surprisingly, 
the short peptides reveal homology to numerous 
proteins.  The picture is further complicated by an 
obvious fact that some epitopes may not be continuous, 
or may include posttranslational modification and, 
hence, would not be detected in a trivial homology 
search. The key assumption that Ionov made is that an 
immunogenic protein is likely to be targeted by 
multiple antibodies, and at least some of them would 
have continuous epitopes. If this is the case, one may 
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expect the same protein identified in the searches for 
homology with multiple selected peptides. Indeed, the 
report gives several examples of such proteins. At least 
one of them, fucosyltransferase 6, was confirmed to be 
overexpressed in the tumor from the patient who was 
the donor of the respective serum sample. 
The idea to use phage libraries as means of 
interrogating cancer-directed immunity is not entirely 
new. However, the prior work relied on a cumbersome 
strategy of choosing a single phage-displayed peptide 
and using it to raise rabbit polyclonal antibodies [2]. 
The assumption was that the peptide would be a good 
enough mimic of the original protein, so that the 
antibodies raised against the former could be used to 
identify the latter. Although successfully used in the 
original study, this strategy is not readily scaled up for 
the analysis of multiple peptides. Also, the choice of an 
individual peptide to pursue is not an easy one: if it is 
made in favor of a peptide, which is consistently bound 
by immunoglobulins from multiple patients, less 
commonly targeted epitopes have to be ignored, even if 
they all actually correspond to one protein.  
A simple and elegant solution proposed by Ionov is 
to rely on bioinformatics to look for candidate proteins, 
even at the risk of ignoring the peptides which do not 
mimic linear epitopes.  Despite some obvious inherent 
limitations, this promises to be a very fruitful approach, 
as it is readily interfaced with high-throughput 
sequencing and could be used to pick proteins that are 
targeted through distinct epitopes either in a single 
patient or in different individuals. The next natural step 
is to expand this methodology to a larger patient 
population and to various cancer types in an attempt to 
identify the signature of common antigens, which 
could be used for diagnostic purposes and might yield 
some clues to the molecular pathology of the disease. 
Another important issue is whether the reactivity to the 
identified antigens changes predictably during growth, 
remission and recurrence of the disease. If this is 
indeed the case, one might be able to select a set of 
peptides that are recognized by tumor-specific 
antibodies in a given patient and could be used to probe 
the state of the disease using a simple blood test. 
Potential complication reside in the choice of negative 
control antibodies, which are used for pre-absorption of 
the phage library, and discriminating between tumor-
specific antigens and any additional auto-antigens that 
may arise in an individual. It is also tempting to 
compare the sequences of the selected peptides to the 
databases of viral proteins, as an attempt to examine 
the possible viral contribution to the disease. 
While the tumor-associated antigens revealed by 
immuno-profiling may be highly significant for 
diagnostic purposes, one has to be cautious not to 
exaggerate their mechanistic roles in disease 
progression. Such antigens may be mere byproducts of 
engaged oncogenic pathways or purely serendipitous 
variations in cancer  cells.  In this aspect, immuno-
profiling strategy of Ionov joins other methods of 
comparative analysis, which complement, rather than 
replace the function-based gene discovery techniques 
(discussed elsewhere [3-4]) and other conventional 
techniques of molecular oncology. 
Certainly, a large number of tumor-associated 
antigens are not recognized as continuous epitopes. At 
this time, one cannot conclude whether the omission of 
such epitopes from consideration does or does not 
critically impair the technology. In fact, for as long as 
the interaction of these epitopes with antibodies is 
faithfully mimicked by the selected peptides, those 
peptides might be useful in conjunction with 
appropriate adjuvants and chemotherapy to boost the 
anti-tumor activity of the patient’s immune system (as 
is done with conventional peptide cancer vaccines [5]) 
even if the actual antigen remains unknown. The utility 
of this approach is yet to be tested and has to be 
evaluated against the competing technologies, such as 
whole-cell tumor vaccines [6]. 
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